WE'RE GOING DIGITAL!
Kisaco Research is committed to providing attendees across all of our events with the best possible experience, it’s for this reason we’ve decided to go digital and embrace the amazing new technology that enables us to deliver a virtual event.
Why Attend
With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs, eyes are focused on how much further protein degradation-based therapeutics will continue to grow
within the pharmaceutical industry.
Following huge success in September 2020, the 3rd European Protein Degradation Congress, returns to Switzerland 28th-30th September 2021, where you can hear the most up to date and relevant information for the broad range of topics in the field of targeted
protein degradation.
New areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown.
Leading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway, providing a clearer picture on what makes a good, or not good, target for degradation.
The Virtual Experience
Top 10 benefits
- Tailor Your Agenda
- More Audience Participation
- Improved Audience Visibility
- On-Demand Content
- High Quality Speakers
- More Networking Opportunities
- Save Time & Money
- Increased Content
- More insights
- Business Development Opportunities - Talk to our team to find out out more [email protected].
Platform Preview
Poster Submission 2021
Looking to showcase your recent work to the protein degradation community?
Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.
Poster abstract submission deadline is on 17 August 2021. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
If you have any questions please contact [email protected]
Previous Attendees Include
highlights from 2019
Talk to our speakers about...
1. How to exploit protein homeostasis to identify new proteins for degradation
2. How to find new E3 ligase recruiters
3. What does the next generation of targeted protein degradation products look like?
4. How can chemo-proteomics be used to make the ‘undruggable’ druggable?
5. Structural-based design of PROTAC through crystallography techniques
6. Furthering our understanding of the ubiquitin space.
7. New synthetic molecular glue approaches from auxin scaffolds
8. How mechanistic understanding of the DUBs space is applicable to targeted protein degradation
9. How well do PROTACs work in clinical application – insights into the first human trial
10. Key medicinal chemical considerations for moving from a PROTAC/molecular glue probe to drug
Audience Breakdown
What attendees say
2020 Speakers
Nico Thoma
Alfred Goldberg
Keith Hornberger
Keith Hornberger is Director of Chemistry at Arvinas, Inc., where he leads the medicinal chemistry team supporting the discovery of PROTAC™ targeted protein degraders for oncology. Prior to joining Arvinas in 2016, Keith held multiple positions in preclinical drug discovery at GlaxoSmithKline, OSI Pharmaceuticals (a subsidiary of Astellas), and Boehringer Ingelheim over a span of 14 years. Keith completed his Ph.D. in organic chemistry at Columbia University in 2002.
Kirti Sharma
Manfred Koegl
I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.
Andreas Martin
Kristin Riching
Kristin received her Ph.D. in Biomedical Engineering from the University of Wisconsin – Madison, where she studied the structural and mechanical properties of collagen fibre networks and their effects on breast cancer cell migration in invasive ductal carcinoma. She joined Promega in 2014 as a postdoctoral researcher to study the pharmacology of ligand-dependent responses within the ErbB signalling network. Currently, she is a Senior Scientist developing technologies and approaches for live cell characterization of protein degradation and protein interactions within the ubiquitin proteasome pathway.
Markus Quessier
Radoslaw Nowak
Laura Itzhaki
Cristina Mayor-Ruiz
Markus Muellner
Stina Lundgren
Boxun Lu
Michael Dabrowski
Michael Dabrowski, PhD, co-founder and CEO of Pelago Bioscience. Michael began his Drug Discovery career as an industrial Masters- and PhD-student at Novo Nordisk and worked as a postdoc on Type 2 diabetes. He then developed a long career at AstraZeneca: from senior scientist and technology expert, to project and scientific leader and manager. Through his diverse career, Michael has built a vast industry network and accumulated experience in Drug Discovery, from active laboratory activity, assay and test development, personnel manager, project management and overall portfolio responsibilities. Michael’s key strengths and experience are in establishing cross functional collaborations and Business Development.
Frank Mercurio
Gopal Sapkota
Zhengnian Li
Andy Pike
Simon Bailey
Matthias Wittwer
Willem Nissink
Zuzanna Kozicka
I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.
Dr. Alex Satz
Danette Daniels
2020 Partners
Expertise Partners
Promega
Website: https://www.promega.com
Promega Corporation is a world leader in providing innovative solutions to the life sciences. We develop bioluminescent technologies that deliver more biologically relevant data for small and large molecule drug discovery. We are the commercial leader in offering sensitive, real-time assays for PROTACs and Protein Degradation. Is my target protein degraded? Is it recruited to the proteasome? Is my PROTAC cell permeable? Speak with a Promega representative to learn how to answer these questions. For more information www.promega.com.
Pelago Bioscience AB
Website: https://www.pelagobio.com/
Pelago Bioscience AB established in 2013 provides and develops the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions, to accelerate drug discovery and diagnostics development. CETSA® provides a quantitative measure of target engagement and the biophysical readout of affinity, and adds real value to existing efficacy assays. We deliver complete target engagement hit confirmation data sets, develop and validate assays for use in screening cascades, and profile candidate drugs based on the CETSA® method, tailored to the project need.
Event Partners
Fluidic Analytics
Website: https://www.fluidic.com/
Fluidic Analytics- Understand the machinery of life
With the right tool, protein researchers can change the world around us.
Our award-winning technologies open doors for scientists to understand proteins and their behavior better than ever before. By characterizing proteins and their interactions, scientists can make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. Our revolutionary technologies give researchers a fundamentally new way to analyze proteins without compromise, because we truly believe the right tools in the right hands will change the world.
Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
BioTheryX
Website: https://www.biotheryx.com/
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven clinical and commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule is currently in Phase I clinical trial for Acute Myeloid Leukemia and high-risk MDS and our lead protein degradation “molecular glue” molecule (Protein Homeostatic Modulator or PHM®) will be in the clinic in 2021 for hematological malignancies.
Aurelia Biosciences
Website: https://www.aureliabio.com/
Aurelia Bioscience is a UK based pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner. They work in early stages of the drug discovery pipeline including target identification and validation, hit identification, hit to lead as well as lead identification and optimisation.
Bio-Techne
Website: http://www.tocris.com/tpd
Bio-Techne offers a complete solution for Targeted Protein Degradation research and development. To support scientists working in this rapidly growing field, we provide a unique range of tools and reagents as well as custom services.
- Active Degraders and Degrader Building Blocks: The Tocris brand has pioneered commercialization of tool Degraders for investigating the phenotypic consequences of targeted protein knockdown. Tocris also supplies chemical building blocks to enable researchers to generate their own Degraders and offers custom synthesis of bespoke panels of Degrader Building Blocks.
- Ubiquitin Proteasome System (UPS) Proteins and Assays: As the global leader in UPS related products, Boston Biochem provides proteins, antibodies and assay kits, as well as custom expertise in protein purification, characterization, modification, and assay development.
- Assays for Protein Degradation: Simple WesternTM systems from ProteinSimple simplify and accelerate the detection of Degrader-mediated protein knockdown by automating the entire protein separation and detection process.
NanoTemper
Website: https://nanotempertech.com/
NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on enabling researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.
Liverpool ChiroChem
Website: https://www.liverpoolchirochem.com/
Liverpool ChiroChem (LCC) is a chemical technology innovator that produces chiral small molecules for biotech/pharmaceutical R&D. As the Home of Chiral N-Heterocycles, our initial focus is the production and supply of sp3-rich chiral N- heterocycles, readily accessible, chirally pure and available on scale. The harnessed expert synthetic technologies provide efficient access to a variety of novel, compact, chiral building blocks, in order to facilitate access to new chemical space for hit identification and potential further hit expansion. Finally, our proprietary products are ideally suited for DNA-Encoded Library synthesis and Fragment Based Lead Discovery, which many medicinal chemists consider to be the two leading areas of modern-day drug discovery.
WuXi AppTec
Website: https://www.wuxiapptec.com/
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."
Selvita
Website: https://selvita.com/
Selvita is an integrated service company providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development.
The company was established in 2007 and currently employs 450 professionals. It is headquartered in Krakow, Poland, and foreign offices located in Boston, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK.
Since its incorporation in 2007 it has provided efficient and effective drug discovery support for pharma and biotech companies’ programmes based on broad capabilities and thorough experience in small molecule drug discovery, starting from target validation up to the selection of a clinical candidate. Its laboratories are both GLP- and GMP-certified.
Selvita scientific team aims at building strong partnerships and becoming an integral part of clients’ organizations ensuring out-of-the box thinking, strong IP protection and goal achievement.
The Agenda
Please complete the from to receive the full agenda for 2020, including information about the key topics being covered, speakers, and why you should attend.
What you can expect from the 2020 congress:
- 200+ participants from leading industry players within big pharma and biotech along with expert academics in the ubiquitin space.
- An open forum to share the latest in vivo and in vitro data and insights and foster collaboration.
- 18+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
- 3 days of progressing translation of protein degradation probes into safe, effective therapeutics.
Download Agenda
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket prices increase in
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.